Product Design, Manufacturing & Innovation Resources

Neueste Veröffentlichungen und Patente im Bereich der molekularen Onkologie

Publikationen und Patente im Bereich der molekularen Onkologie

Tipp: Zusätzlich zu der unten stehenden Auswahl können Sie unsere 2 gesamten Datenbanken durchsuchen und filtern:

> Kostenloses Tool zur Suche nach Veröffentlichungen < nach Autor, Thema, Stichwörtern, Datum oder Zeitschrift.

> Kostenloses Tool zur Suche nach Patenten < für Patente in englischer Sprache vom Europäischen Patentamt.

Molekulare Onkologie
Molecular oncology leverages advanced Technologien to innovate cancer diagnosis and treatment through genetic and biochemical insights.

Die molekulare Onkologie erforscht die genetischen, epigenetischen und biochemischen Veränderungen, die die Entstehung, das Fortschreiten und die Therapieresistenz von Krebs bedingen. Dieses Forschungsgebiet integriert Hochdurchsatzsequenzierung, molekulare Diagnostik und zielgerichtete Therapien, um onkogene Signalwege, die Inaktivierung von Tumorsuppressorgenen und Wechselwirkungen mit der Tumormikroumgebung aufzuklären. Fortschritte in der molekularen Profilierung, der Biomarker-Entdeckung und der Präzisionsmedizin verändern die Krebsklassifizierung und Behandlungsstrategien grundlegend. Die folgende Zusammenstellung präsentiert die neuesten peer-reviewten Publikationen und patentierten Innovationen und spiegelt die Spitzenforschung zu Onkogenen, Signaltransduktion, Krebsstammzellen, Immunmodulation und molekularen Bildgebungsverfahren wider, die für die translationale Onkologie und klinische Anwendungen unerlässlich sind.

Dies ist unsere neueste Auswahl an weltweiten Veröffentlichungen und Patenten in englischer Sprache zum Thema Molekulare Onkologie, die in vielen wissenschaftlichen Online-Zeitschriften zu den Themen Onkogene, Tumorsuppression, Signaltransduktionswege, Krebsgenomik, Epigenetik bei Krebs, molekulare Biomarker, gezielte Krebstherapie, Krebszellsignalisierung, DNA-Mutation, microRNAs in der Onkologie, Krebsstammzellen, Apoptoseregulation klassifiziert sind, Tumormikroumgebung, Krebsimmuntherapie, Genexpressionsprofile, Chromosomenaberrationen, molekulare Diagnostik, Krebsproteomik, onkogene Stoffwechselwege, Krebsmetastasen, molekulare Mechanismen der Krebsentstehung, Tumorheterogenität, Krebsepigenomik, onkogene Viren, molekulare zielgerichtete Arzneimittel, Krebstranskriptomik, DNA-Reparaturmechanismen, pharmakogenomische Krebsforschung und molekulare Krebspathologie.

Tumor antigens for ovarian cancer and uses thereof

Patent published on the 2026-05-28 in WO under Ref WO2026107594 by UNIV DE MONTREAL [CA] (Perreault Claude [ca], Thibault Pierre [ca], Hardy Marie-pierre [ca], Vincent Krystel [ca])

Abstract: Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is still largely unknown. Novel tumor antigens shared by a large proportion of ovarian tumor cells are described herein. Several of the tumor [...]


Our summary: Novel tumor antigens for high-grade serous ovarian cancer are identified, derived from aberrantly expressed genomic sequences. These antigens are not present in normal tissues and may elicit immune responses. The study discusses their potential use in treatments, including nucleic acids, compositions, cells, and vaccines.

tumor antigens, ovarian cancer, immunotherapy, vaccines

Patent

Methods for predicting and improving the efficacy of car t-cell therapy

Patent published on the 2026-05-06 in EP under Ref EP4736874 by UNIV ZUERICH [CH] (Magnani Chiara Francesca [ch], Ponzo Marianna [ch], Gaipa Giuseppe [it], Biondi Andrea [it])

Abstract: [0001] Disclosed is a treatment with a combination of inhibitors useful to improve the effectiveness of CAR T-cell therapies by inhibiting hypoxia, VEGF pathways and inflammation at the tumor microenvironment, thereby enhancing the response to CAR T-cell therapy in tumor patients. There is also disclosed a method for predicting the response to CAR T-cell therapy by determining T cell surface expression markers.[...]


Our summary: The document discusses methods to enhance CAR T-cell therapy effectiveness through inhibitors targeting hypoxia, VEGF pathways, and inflammation. It also presents a predictive method for therapy response based on T cell surface expression markers. These approaches aim to improve patient outcomes in tumor treatments.

CAR T-cell therapy, efficacy prediction, tumor microenvironment, inhibitors

Patent

A fluid processing device for processing droplets

Patent published on the 2026-05-06 in EP under Ref EP4737004 by IMEC VZW [BE] (Yurt Abdulkadir [be], Set Ying Ting [be], Moloudi Reza [be], Vandevelde Bart [be])

Abstract: [0001] The present invention relates to a fluid processing device for processing droplets. The device comprises a plate-like structure comprising a plurality of functional pixels. Each functional pixel is adapted to perform multiple operations on a droplet located on the pixel. Specifically, each pixel can selectively carry out at least two of the following processing operations: manipulating the droplet (e.g., its position), applying heat to the droplet, and subjecting the droplet to a magnetic[...]


Our summary: The invention is a fluid processing device designed for droplet manipulation. It features a plate-like structure with functional pixels that can perform multiple operations on droplets. This device integrates various microfluidic functions into a compact platform for applications in biochemical analysis and drug discovery.

microfluidics, droplet manipulation, functional pixels, biochemical analysis

Patent

A simplified molecular diagnostic workflow for detecting human immunodeficiency virus 1 (hiv-1) and hepatitis c virus (hcv)

Patent published on the 2026-04-23 in WO under Ref WO2026081001 by HIS MAJESTY THE KING IN RIGHT OF CANADA AS REPRESENTED BY THE MINI OF HEALTH [CA] (Tang David [ca], Nguyen Kelvin [ca], Michalak Karen [ca], Lacap Phil [ca], Kim John [ca], Mclaren Paul [ca])

Abstract: Described herein is a singleplex RT-LAMP-based tests using modified primer sets. Contrived whole blood samples containing HIV-1 or HCV virions were diluted in equal parts water and loaded directly into optimized RT-LAMP master mixes. To mitigate cold-chain storage dependence, RT-LAMP reactions were performed using a lyophilized master mix. The reactions were heated for, for example 30 minutes using a hand-held, battery-powered heating device for simultaneous virion lysis and amplification.[...]


Our summary: This study presents a simplified workflow for detecting HIV-1 and HCV using singleplex RT-LAMP tests with modified primers. Whole blood samples containing the viruses were diluted and directly loaded into optimized master mixes. A lyophilized master mix allowed for reactions to be performed without cold-chain storage, using a portable heating device for amplification.

RT-LAMP, HIV-1, HCV, molecular diagnostics

Patent

Combination of cancer vaccines and anti-trem2 agents for enhanced cancer immunotherapy

Patent published on the 2026-04-23 in WO under Ref WO2026085270 by UNIV TEXAS [US] (Gubin Matthew [us])

Abstract: The present disclosure generally relates to methods for treating cancer, and more specifically to combinatorial approaches using cancer vaccines together with agents targeting the TREM2 receptor to enhance anti-tumor immune responses. The invention includes methods of administering cancer vaccines in combination with anti-TREM2 agents. This approach enhances anti-tumor immunity by expanding tumor-specific T cells while reducing immunosuppressive macrophages in the tumor microenvironment. Additio[...]


Our summary: This disclosure presents methods for treating cancer using a combination of cancer vaccines and anti-TREM2 agents. The approach enhances anti-tumor immunity by increasing tumor-specific T cells and decreasing immunosuppressive macrophages. It also explores the combination of these agents with immune checkpoint inhibitors for improved therapeutic outcomes.

cancer vaccines, anti-TREM2 agents, immunotherapy, tumor microenvironment

Patent

Docking peptides and related antibody-based drug conjugates

Patent published on the 2026-04-23 in US under Ref US20260109780 by SONNET BIOTHERAPEUTICS INC [US] (Cini John K [us], Evans Nick [gb])

Abstract: [0000] Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment. [0000] In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a c[...]


Our summary: Novel docking peptides enable controlled attachment of drug moieties for targeted delivery. Antibody-based drug conjugates enhance drug payload delivery to tumor sites. The technology allows for a controlled drug-to-antibody ratio for improved therapeutic efficacy.

docking peptides, antibody-drug conjugates, tumor targeting, drug delivery

Patent

Glioblastoma-Derived Extracellular Vesicles Modulate &gamma;&delta; T Lymphocytes Through a MIC-Dependent Mechanism

Published on 2026-02-03 by Micaela Rosato, Paula Saibene Vlez, Alejandra Infante Cruz, Matas A. Pibuel, Federico Fuentes, Mnica Vermeulen, Juan Iturrizaga, Pablo E. Espil, Silvia Berner, Gabriela V. Salamone, Carolina C. Jancic @MDPI

Abstract: Glioblastoma (GBM) is the most aggressive and common primary brain tumor, with a median survival of less than a year after diagnosis. &amp;gamma;&amp;delta; T lymphocytes are immune cells that can migrate to tumors and induce malignant cells&amp;rsquo; apoptosis. Our previous in silico studies showed that higher &amp;gamma;&amp;delta; T-cell infiltration in GBM correlates with better patient survival, and in vitro experiments showed that GMB supernatants promote an antitumora[...]


Our summary: Glioblastoma-derived extracellular vesicles (EVs) modulate gamma delta T lymphocytes through a MIC-dependent mechanism. Increased CD69 expression, cytotoxicity, and cytokine production in T cells were observed following EV interaction. These findings offer insights for targeted immunotherapy development in glioblastoma patients.

Extracellular vesicles, Glioblastoma, Gamma delta T lymphocytes, Immunotherapy

Publication

Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling

Published on 2026-02-03 by Macarena Rodrguez-Serrano, Elena Martn-Garca, Patricia Alonso-Andrs, Elisa Conde-Moreno, Hctor Pian, Javier del Moral-Salmoral, Nunzio Alcharani, Miriam Menacho-Romn, Lorena Crespo-Toro, Miren Edurne Ramos-Muoz, Carlos Zaragoza, Luis Miguel Rincn, Mara G. Barderas, Mara Laura Garca-Bermejo @MDPI

Abstract: Myocardial infarction (MI) triggers complex pathological processes, including inflammation, hypoxia, and fibrotic remodeling. MicroRNAs (miRNAs) have emerged as promising biomarkers for cardiovascular injury; however, their expression dynamics along processes remain underexplored. We used an in vivo rat model of permanent coronary occlusion to study the molecular alterations associated with MI and its resolution in a temporal mode, including five experimental groups with five animals in each: sh[...]


Our summary: This study investigates the dynamic expression of microRNAs as biomarkers for cardiac ischemia following myocardial infarction. Using a rat model, it identifies specific miRNAs that correlate with the progression and resolution of myocardial injury over time. The findings suggest that these miRNA signatures can serve as noninvasive indicators of cardiac stress and potential therapeutic targets.

microRNA, cardiac ischemia, biomarkers, myocardial infarction

Publication

Behandelte Themen: Molekulare Onkologie, genetische Veränderungen, epigenetische Veränderungen, biochemische Veränderungen, Hochdurchsatzsequenzierung, molekulare Diagnostik, zielgerichtete Therapeutika, onkogene Signalwege, Tumorsuppressorgene, Tumormikroumgebung, Entdeckung von Biomarkern, Präzisionsmedizin, Krebsklassifizierung, Immunmodulation, molekulare Bildgebung, translationale Onkologie, klinische Anwendungen, von Experten begutachtete Veröffentlichungen, patentierte Innovationen ISO 15189, ISO 9001, ISO/IEC 17025, CLSI-Richtlinien und ASTM E2876.

Historischer Kontext

1965
1970
1980
1980
1990
1960
1969
1976-05-28
1980
1990

(wenn das Datum unbekannt oder nicht relevant ist, z. B. „Strömungsmechanik“, wird eine gerundete Schätzung seines bemerkenswerten Auftretens bereitgestellt)

Bilder in voller Größe und Downloads sind nur für registrierte Mitglieder 100% kostenlos verfügbar.

> Login <